INTRODUCTION: MiT translocation renal cell carcinomas (TRCC) predominantly occur in younger patients with only 25% of patients being over 40 years. TRCC contains two main subgroups with translocations involving 6p21 or Xp11.2. Herein we present 10 cases. MATERIALS: Eight cases were treated at main author's institution (identified among 1653 (0.48%) cases of kidney tumours in adults). Two cases were retrieved from the Pilsen (CZ) Tumour Registry. RESULTS: Six cases were type Xp11.2 and four 6p21; 7 female, 3 male patients; Xp11.2 4:2, 6p21 3:1. The mean age 49 years (range: 21-80), 5 patients (50%) over 40 years. The mean age of the group with Xp11.2 TRCCs was 55 (median 51) and 6p21 41 (32) years. One female with a 6p21 tumour (24 years) underwent nephrectomy at 4 months of pregnancy. Stage (UICC, 7th ed. 2009) was 5xI, 3xIII, 2xIV. The mean size of tumour was 80 (40-165) mm. The mean follow-up was 33.2 (1-92) months. In patients with 6p21 tumours, one (25%) died after 3 months due to widely metastatic disease. In patients with Xp11.2 tumours, 3 (50%) succumbed due to metastatic disease (range 1-8 months). Three patients with Xp11.2 are alive at 7, 52 and 92 months of follow-up, were diagnosed at early stage (T1a). CONCLUSION: TRCCs were more common in females. Patient with 6p21 tumours were younger than those with Xp11.2. Both types have definitive malignant potential Type Xp11.2 seems to be a more aggressive neoplasm than 6p21. The case with metastatic 6p21 tumour is the 4th case described in the English literature.

Department of Diagnostic Pathology Kochi Red Cross Hospital Kochi Japan

Department of Pathology Faculty Hospital in Pilsen Pilsen Czech Republic

Department of Pathology Faculty Hospital in Pilsen Pilsen Czech Republic ; Faculty of Medicine in Pilsen Charles University Prague Prague Czech Republic

Department of Pathology National University Health System Singapore Singapore

Department of Radiology Pilsen Czech Republic

Department of Radiology Pilsen Czech Republic ; Faculty of Medicine in Pilsen Charles University Prague Prague Czech Republic

Department of Urology Faculty Hospital E Beneše 13 Pilsen 305 99 Czech Republic ; Faculty of Medicine in Pilsen Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE, Ladanyi M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149–1160. doi: 10.1097/PAS.0b013e318031ffff. PubMed DOI

Armah HB, Parwani AV, Surti U, Bastacky SI. Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature. Diagn Pathol. 2009;4:15. doi: 10.1186/1746-1596-4-15. PubMed DOI PMC

Arnoux V, Long JA, Fiard G, Pasquier D, Bensaadi L, Terrier N, Rambeaud JJ, Descotes JL. Xp11.2 translocation renal carcinoma in adults over 50years of age: About four cases. Prog Urol. 2012;22(15):932–937. doi: 10.1016/j.purol.2012.06.009. PubMed DOI

Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656–670. doi: 10.1097/PAS.0b013e3181609914. PubMed DOI

Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010;116(22):5219–5225. doi: 10.1002/cncr.25512. PubMed DOI PMC

Franzini A, Picozzi SC, Politi PL, Barana L, Bianchi F, Alfano G, Gatti G, Fanciullacci F, Gariboldi M, Strada M, Leone BEA. case of renal cancer with TFE3 gene fusion in an elderly man. Clinical, radiological and surgical findings. Urol Int. 2007;78(2):179–181. doi: 10.1159/000098080. PubMed DOI

Gaillot-Durand L, Chevallier M, Colombel M, Couturier J, Pierron G, Scoazec JY, Mege-Lechevallier F. Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein. Pathol Res Pract. 2013;209(2):83–89. doi: 10.1016/j.prp.2012.10.013. PubMed DOI

Hora M, Hes O, Eret V, Urge T, Klečka J, Ferda J, Chudáček Z, Vanček T, Michal M. Translokační renální karcinom Xp11. 2 typu ASPL/TFE3. Ces Urol. 2008;12(3):186–193.

Hora M, Hes O, Urge T, Eret V, Klecka J, Michal M. A distinctive translocation carcinoma of the kidney [“rosette-like forming” t (6;11), HMB45-positive renal tumor] Int Urol Nephrol. 2009;41(3):553–557. doi: 10.1007/s11255-008-9495-8. PubMed DOI

Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I, Ishikawa Y. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t (6;11) translocation. Am J Surg Pathol. 2012;36(1):35–42. doi: 10.1097/PAS.0b013e3182293ec3. PubMed DOI

Ishihara A, Yamashita Y, Takamori H, Kuroda N. Renal carcinoma with (6;11) (p21; q12) translocation: report of an adult case. Pathol Int. 2011;61(9):539–545. doi: 10.1111/j.1440-1827.2011.02711.x. PubMed DOI

Kato H, Kanematsu M, Yokoi S, Miwa K, Horie K, Deguchi T, Hirose Y. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: radiological findings mimicking papillary subtype. J Magn Reson Imaging. 2011;33(1):217–220. doi: 10.1002/jmri.22392. PubMed DOI

Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, Waldert M, Marberger M, Susani M, Haitel A. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation incidence, characteristics, and prognosis. Am J Clin Pathol. 2012;137(5):761–768. doi: 10.1309/AJCPQ6LLFMC4OXGC. PubMed DOI

Koie T, Yoneyama T, Hashimoto Y, Kamimura N, Kusumi T, Kijima H, Ohyama C. An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol. 2009;16(3):333–335. doi: 10.1111/j.1442-2042.2008.02231.x. PubMed DOI

Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170–1176. doi: 10.1158/1078-0432.CCR-08-1183. PubMed DOI

Koo HJ, Choi HJ, Kim MH, Cho KS. Radiologic-pathologic correlation of renal cell carcinoma associated with Xp11.2 translocation. Acta Radiol. 2013;54(7):827–834. doi: 10.1177/0284185113484019. PubMed DOI

Kuroda N, Katto K, Tanaka Y, Yamaguchi T, Inoue K, Ohara M, Mizuno K, Hes O, Michal M, Lee GH. Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions. Med Mol Morphol. 2010;43(2):86–90. doi: 10.1007/s00795-008-0423-x. PubMed DOI

Kuroda N, Mikami S, Pan CC, Cohen RJ, Hes O, Michal M, Nagashima Y, Tanaka Y, Inoue K, Shuin T, Lee GH. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. Histol Histopathol. 2012;27(2):133–140. PubMed

LaGrange CA, Lele SM, Strup SE. Renal cell carcinoma associated with TFE3 gene fusion in an elderly woman. Urology. 2007;70(3):590–e11-2. doi: 10.1016/j.urology.2007.06.1096. PubMed DOI

Liu YC, Chang PM, Liu CY, Yang CY, Chen MH, Pan CC, Chen MH. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Jpn J Clin Oncol. 2011;41(11):1277–1281. doi: 10.1093/jjco/hyr140. PubMed DOI

Liu K, Xie P, Peng W, Zhou Z. J Magn Reson Imaging. 2013. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions: Findings on MRI and computed tomography imaging. PubMed

Morii A, Fujiuchi Y, Nomoto K, Komiya A, Fuse H. Rapidly progressing renal cell carcinoma associated with Xp11.2 translocations: a case report. J Med Case Rep. 2012;6(1):164. doi: 10.1186/1752-1947-6-164. PubMed DOI PMC

Nelius T, Al-Khalil I, Vordermark J, Rinard-Holden K, Cammack T, Mamlok V, Filleur S. TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature. Case Rep Med. 2011;2011:432917. PubMed PMC

Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, Narita S, Horikawa Y, Satoh S, Habuchi TA. case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16(5):577–580. doi: 10.1007/s10147-010-0154-6. PubMed DOI

Pecciarini L, Cangi MG, Lo Cunsolo C, Macri E, Dal Cin E, Martignoni G, Doglioni C. Characterization of t (6;11) (p21; q12) in a renal-cell carcinoma of an adult patient. Genes Chromosomes Cancer. 2007;46(5):419–426. doi: 10.1002/gcc.20422. PubMed DOI

Rais-Bahrami S, Drabick JJ, De Marzo AM, Hicks J, Ho C, Caroe AE, Argani P. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 2007;70(1):178–e3-6. doi: 10.1016/j.urology.2007.03.037. PubMed DOI

Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, Jiang SJ, Wang Y, Wang X, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Wang JD, Zhou XJ. Renal cell carcinomas with t (6;11) (p21; q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36(9):1327–1338. doi: 10.1097/PAS.0b013e31825aafb5. PubMed DOI

Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, Zhou XJ, Huang W, Tan PH, Maclennan GT, Cheng L. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37(6):804–815. doi: 10.1097/PAS.0b013e31827e17cb. PubMed DOI

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P. ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37(10):1469–1489. doi: 10.1097/PAS.0b013e318299f2d1. PubMed DOI

Suarez-Vilela D, Izquierdo-Garcia F, Mendez-Alvarez JR, Miguelez-Garcia E, Dominguez-Iglesias F. Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features. Int J Surg Pathol. 2011;19(4):506–509. doi: 10.1177/1066896909340531. PubMed DOI

TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations